LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9750
+0.2250 (+6.0000%)
As of 2:03PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.7500
Open3.7000
Bid3.9500 x 100
Ask4.0000 x 2000
Day's Range3.7000 - 4.0000
52 Week Range2.1000 - 6.4960
Volume47,327
Avg. Volume108,227
Market Cap118.1M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1870
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 hours ago

    aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference

    SAN DIEGO, Nov. 21, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, ...

  • Associated Press5 days ago

    Atyr Pharma reports 3Q loss

    The San Diego-based company said it had a loss of 43 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswire7 days ago

    aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update

    -Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter-. -Selection of antibody for ORCA program on-track for this quarter-. SAN DIEGO, Nov. 14, 2017-- aTyr Pharma, Inc., a biotherapeutics ...

  • GlobeNewswire20 days ago

    aTyr Pharma Announces Leadership Transition

    John Mendlein Transitions from CEO to Non-Executive Board Member, Dr. Sanjay Shukla Appointed President and CEO–. SAN DIEGO, Nov. 01, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the ...

  • Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
    Zackslast month

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

  • How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
    Simply Wall St.2 months ago

    How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?

    For aTyr Pharma Inc’s (NASDAQ:LIFE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More...

  • GlobeNewswire2 months ago

    aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society

    SAN DIEGO, Sept. 27, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine ...

  • GlobeNewswire3 months ago

    aTyr Pharma to Present at Two Upcoming Investor Conferences in September

    SAN DIEGO, Sept. 05, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new pathway insights from human Physiocrine ...

  • The Wall Street Journal3 months ago

    [$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift

    ATyr Pharma Inc., whose share price has been falling since it went public in 2015, is getting a $45.8 million lift from a group of investors that include a firm that backed the company while it was private....

  • GlobeNewswire3 months ago

    aTyr Pharma Announces $45 Million Equity Financing

    SAN DIEGO, Aug. 28, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the Resokine pathway, to treat patients suffering ...

  • Associated Press3 months ago

    Atyr Pharma reports 2Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...

  • Associated Press6 months ago

    Atyr Pharma reports 1Q loss

    The San Diego-based company said it had a loss of 56 cents per share. In the final minutes of trading on Thursday, the company's shares hit $3.10. A year ago, they were trading at $3.01. _____ This story ...

  • PR Newswire8 months ago

    aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors

    SAN DIEGO, April 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Mr. Jeffrey S. Hatfield, as an independent board director, to aTyr Pharma's board of directors, effective immediately. Mr. Hatfield brings relevant industry operations experience and expertise to aTyr at an important and exciting time for aTyr's growth. Jeffrey S. Hatfield served as President, Chief Executive Officer of Vitae Pharmaceuticals from March 2004 through October 2016 when Vitae was acquired by Allergan, plc. During his tenure at Vitae, Mr. Hatfield focused the company on high value therapeutic areas with significant global unmet medical need, including autoimmune disorders, diabetes, immuno-oncology and more.

  • Associated Press8 months ago

    Atyr Pharma reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 53 cents. For the year, the company reported a loss of $57.9 million, or $2.44 per share. In the final minutes of trading on Thursday, ...

  • PR Newswire8 months ago

    aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases

    SAN DIEGO, March 15, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the issuance of US Patent Number 9,428,743, which represents the successful completion of an important aTyr milestone – the issuance of patents that cover Physiocrines derived from all 20 human tRNA synthetases. In addition, the patent portfolio covers all of aTyr's three current programs in three different therapeutic areas. "The USPTO issuance of our '743 patent represents one example of the many efforts of our scientists to meticulously explore and validate this new biology that is generating a pipeline of therapeutics based on Physiocrines," said John Mendlein, Ph.D., CEO aTyr Pharma.

  • PR Newswire9 months ago

    aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™

    SAN DIEGO, March 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to Resolaris™ for the treatment of limb girdle muscular dystrophy (LGMD) patients. "As the week of International Rare Disease day concludes, we remind ourselves of our important mission to our patients – to develop new medicines based on our pioneering efforts in Physiocrine biology that we hope form the basis of meaningful changes to the lives of patients impacted by rare diseases worldwide.